Leapfrog Remedies Unveils DAILY, UK's First Lactoferrin‑Based Daily Supplement

Why It Matters

The introduction of DAILY marks the first time a high‑purity lactoferrin supplement has been positioned as a daily, stand‑alone product in the UK, challenging the dominance of colostrum‑based formulas. By coupling lactoferrin with clinically validated micronutrients, Leapfrog offers a more precise nutritional tool that aligns with emerging consumer demand for evidence‑based, single‑ingredient solutions. This could accelerate scientific literacy around lactoferrin, drive further research funding, and reshape supplement formulation standards across the nutraceutical industry. Moreover, the product’s focus on perimenopausal women addresses a long‑standing gap in non‑hormonal support options, potentially opening a sizable market segment. If successful, DAILY may encourage other brands to develop targeted, age‑specific formulations, fostering a more nuanced approach to everyday nutrition that moves beyond the one‑size‑fits‑all multivitamin model.

Key Takeaways

• Leapfrog Remedies launched DAILY, the UK's first lactoferrin‑based daily supplement.
• Each tablet contains 100 mg lactoferrin (>95 % purity) plus vitamins D3, K2, C, E and zinc.
• Pricing: £27 (~$34) for 15 tablets; subscription at £21.60 (~$27.5).
• Target demographic: women 35‑55, with broader appeal to all adults seeking immune and bone health.
• Launch reflects a broader shift toward ingredient‑focused, clinically backed nutraceuticals in the UK market.

Pulse Analysis

Leapfrog’s entry into the daily supplement arena with a lactoferrin‑centric product is both a strategic differentiation and a test of market appetite for high‑purity bioactives. Historically, the UK supplement space has been dominated by broad‑spectrum multivitamins and protein powders; a move toward a single, scientifically validated protein aligns with a global trend seen in the U.S. and Asia where consumers gravitate toward ‘functional’ ingredients with clear mechanisms of action. By pricing DAILY competitively against premium colostrum offerings, Leapfrog is betting that consumers will prioritize purity and targeted benefit over brand familiarity.

The timing is also noteworthy. Post‑pandemic health consciousness has heightened demand for immune‑supporting products, yet the market is becoming saturated with vague claims. Leapfrog’s reliance on peer‑reviewed evidence—citing over 11,000 studies and a recent 2025 clinical trial—provides a narrative that can cut through the noise. If the product gains traction, it could pressure larger players to substantiate their claims with comparable data, potentially ushering in a new era of transparency and research‑driven marketing in the nutraceutical sector.

Finally, the focus on perimenopausal women could catalyze a wave of gender‑specific formulations that address hormonal transitions without resorting to hormone therapy. This niche, traditionally underserved by mainstream supplement brands, offers a lucrative growth avenue. Should Leapfrog successfully capture this segment, it may inspire a cascade of tailored products, reshaping how the industry approaches life‑stage nutrition and reinforcing the importance of evidence‑based ingredient selection.